Stockscreener 앱 받기
172.59
0.71%
-1.23
전일 마감가:
$173.82
열려 있는:
$173.54
하루 거래량:
3.36M
Relative Volume:
1.23
시가총액:
$49.47B
수익:
$20.87B
순이익/손실:
$1.50B
주가수익비율:
32.94
EPS:
5.24
순현금흐름:
$2.59B
1주 성능:
+0.71%
1개월 성능:
-16.40%
6개월 성능:
-22.22%
1년 성능:
-23.90%
1일 변동 폭
$171.65
$173.80
1주일 범위
$171.65
$176.43
52주 변동 폭
$163.33
$251.99
벡톤 디킨슨 Stock (BDX) Company Profile
명칭
Becton Dickinson Co
전화
(201) 847-6800
주소
ONE BECTON DR, FRANKLIN LAKES
BDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
벡톤 디킨슨 Stock (BDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-05-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2022-07-11 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 재개 | Raymond James | Mkt Perform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 재개 | Goldman | Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-07 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-02-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-01-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-05-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 개시 | Deutsche Bank | Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-06-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-04-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-01-19 | 재개 | BofA/Merrill | Buy |
| 2018-01-05 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-01-05 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2017-12-29 | 재확인 | Deutsche Bank | Buy |
모두보기
벡톤 디킨슨 주식(BDX)의 최신 뉴스
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - BD Newsroom
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Becton Dickinson Sues Baxter Over Infusion Pump Patents - Law360
Becton Dickinson at Bank of America Conference: Navigating Challenges and Opportunities - Investing.com Nigeria
Transcript : Becton, Dickinson and Company Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Judge declares mistrial in punitive damages phase in Walker v. BD - The Covington News
Becton Dickinson Says Baxter Infringes Infusion-Pump Patents (1) - Bloomberg Law News
Sterile Lancets Market Set to Grow | Key Players: Roche, Becton Dickinson, Medtronic - openPR.com
Becton Dickinson (BDX) Unveils Advanced Cell Analyzer - GuruFocus
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies - marketscreener.com
First Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co - Yahoo Finance
Becton Dickinson & Co (BDX) Shares Up 3.73% on May 12 - GuruFocus
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
The Strong Earnings Posted By Becton Dickinson (NYSE:BDX) Are A Good Indication Of The Strength Of The Business - Yahoo
Morgan Stanley Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $196.00 - Defense World
SEC Form 4 filed by Director Byington Carrie L - Quantisnow
Becton, Dickinson downgraded at more firms following Q2 results - MSN
Becton Dickinson downgraded to Neutral from Buy at Goldman Sachs - MSN
Jim Cramer on Becton, Dickinson and Company (BDX): “A Shocking Miss for This Once-Reliable Med Tech Giant” - Insider Monkey
Mistrial declared after jury awards $50M in landmark toxic gas case - AJC.com
Becton Dickinson (NYSE:BDX) Sees 18% Price Dip Over Last Week - Yahoo Finance
Becton Dickinson (BDX) Price Target Lowered by Morgan Stanley | BDX Stock News - GuruFocus
Investors Can Still File Late Claims for Becton, Dickinson & Co $85M Settlement Payouts - TradingView
Morgan Stanley Adjusts Price Target on Becton, Dickinson and Company to $196 From $280, Maintains Overweight Rating - marketscreener.com
Covington resident wins $20 million in case against Becton Dickinson - The Covington News
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales - MSN
벡톤 디킨슨 (BDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
0.19%
자본화:
|
볼륨(24시간):